TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23768214

Group type: EXPERIMENTAL
Intervention: Strength Training (ST)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 16
Study: 21636633

Group type: EXPERIMENTAL
Intervention: Brochure with evidence based risk information and two optional interactive internet modules on risk and diagnostic tests
Number of subjects: 1577

Group type: EXPERIMENTAL
Intervention: Brochure with evidence based risk information
Number of subjects: 1577

Group type: COMPARATOR
Intervention: Official information leaflet of the German colorectal cancer screening programme (control)
Number of subjects: 1577
Study: 19349552

Group type: EXPERIMENTAL
Intervention: Oral sorafenib 400 mg twice daily on days 2 to 19 plus intravenous paclitaxel 225 mg/m2 and intravenous carboplatin AUC 6 on day 1
Number of subjects: 270

Group type: COMPARATOR
Intervention: Placebo plus intravenous paclitaxel 225 mg/m2 and intravenous carboplatin AUC 6 on day 1
Number of subjects: 270
Study: 16737373

Group type: EXPERIMENTAL
Intervention: Interpersonal confrontations (varied in hostility)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Interpersonal confrontations (expressed by either a Black or White person)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hostile confrontations
Number of subjects: 0
Study: 15201249

Group type: COMPARATOR
Intervention: Percutaneous Coronary Intervention (PCI)
Number of subjects: 988

Group type: EXPERIMENTAL
Intervention: Coronary Artery Bypass Grafting (CABG)
Number of subjects: 988

Group type: EXPERIMENTAL
Intervention: CABG
Number of subjects: 988

Group type: COMPARATOR
Intervention: PCI
Number of subjects: 988
Study: 11142539

Group type: EXPERIMENTAL
Intervention: MBTV (MBT plus voucher‐based incentives)
Number of subjects: 60

Group type: COMPARATOR
Intervention: MBT (M plus behavioral coping skills therapy)
Number of subjects: 60

Group type: COMPARATOR
Intervention: M (motivational enhancement)
Number of subjects: 60
Study: 9272298

Group type: EXPERIMENTAL
Intervention: Iloprost infusion for five consecutive days (7-hour infusion)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Iloprost infusion for one day
Number of subjects: 8
Study: 7525359

Group type: EXPERIMENTAL
Intervention: Oral danazol, 50 mg/d for 9 months (group I, n = 21)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Leuprolide depot for 3 months followed by oral danazol, 50 mg/d for 6 months (group II, n = 21)
Number of subjects: 42
Study: 3664913

Group type: EXPERIMENTAL
Intervention: Portex epidural catheter
Number of subjects: 150

Group type: COMPARATOR
Intervention: Vas‐Cath catheter
Number of subjects: 150
Study: 31971061

Group type: EXPERIMENTAL
Intervention: Spanish-DA
Number of subjects: 368

Group type: COMPARATOR
Intervention: English-DA
Number of subjects: 368
Study: 28627230

Group type: EXPERIMENTAL
Intervention: Pharmacoinvasive strategy
Number of subjects: 1866

Group type: EXPERIMENTAL
Intervention: Primary percutaneous coronary intervention
Number of subjects: 1866

Group type: EXPERIMENTAL
Intervention: Scheduled angiography
Number of subjects: 1866

Group type: COMPARATOR
Intervention: Pharmacoinvasive strategy requiring rescue
Number of subjects: 1866
Study: 28431557

Group type: EXPERIMENTAL
Intervention: Lipid-based paste containing vitamin B12
Number of subjects: 600

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 600
Study: 26813135

Group type: COMPARATOR
Intervention: Sevoflurane anesthesia
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Propofol anesthesia
Number of subjects: 30

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 30
Study: 24278915

Group type: EXPERIMENTAL
Intervention: O3 + saline
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: O3 + H2O2
Number of subjects: 20

Group type: COMPARATOR
Intervention: O2 + saline
Number of subjects: 20
Study: 21986980

Group type: EXPERIMENTAL
Intervention: Intravenous paracetamol 15 mg/kg
Number of subjects: 90

Group type: COMPARATOR
Intervention: Intravenous physiological saline (control group)
Number of subjects: 90
Study: 18728172

Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) therapy at 33 microg/kg.d
Number of subjects: 177

Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) therapy at 67 microg/kg.d
Number of subjects: 177

Group type: COMPARATOR
Intervention: Control (untreated)
Number of subjects: 177

Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) therapy
Number of subjects: 177
Study: 17146980

Group type: EXPERIMENTAL
Intervention: New method for active-comparator trials based on location-scale family of distributions
Number of subjects: 0

Group type: COMPARATOR
Intervention: Existing methods for sample size estimation
Number of subjects: 0
Study: 14631268

Group type: EXPERIMENTAL
Intervention: Continuous hormone therapy with rivastigmine (n=59)
Number of subjects: 117

Group type: COMPARATOR
Intervention: Placebo with rivastigmine (n=58)
Number of subjects: 117
Study: 11083612

Group type: EXPERIMENTAL
Intervention: Antegrade nailing
Number of subjects: 100

Group type: COMPARATOR
Intervention: Retrograde nailing
Number of subjects: 100
Study: 9428588

Group type: EXPERIMENTAL
Intervention: Iodopovidone (14 patients)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Bleomycin (8 patients)
Number of subjects: 22
Study: 8087522

Group type: EXPERIMENTAL
Intervention: Chemotherapy (doxorubicin, etoposide, cyclophosphamide, plus methotrexate or cisplatin) and thoracic radiotherapy (total dose of 45, 55, 65 and 61 Gy)
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Chemotherapy and thoracic radiotherapy
Number of subjects: 202
Study: 2669155

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (HCTZ) 25 mg/day
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (HCTZ) 50 mg/day
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (HCTZ) 25 mg plus triamterene (50 mg)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo (during the three-week single-blind period)
Number of subjects: 19
Study: 782970

Group type: EXPERIMENTAL
Intervention: Nose drops
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: Spray device 1
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: Spray device 2
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: Spray device 3
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: Analgesics (for volunteers with fourfold or greater antibody response)
Number of subjects: 193

Group type: COMPARATOR
Intervention: No analgesics (for volunteers with no serological response)
Number of subjects: 193
Study: 29730641

Group type: EXPERIMENTAL
Intervention: Aciclovir
Number of subjects: 3

Group type: COMPARATOR
Intervention: VZIG
Number of subjects: 3
Study: 28151459

Group type: EXPERIMENTAL
Intervention: 1 g/day Nigella sativa (NS-1)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: 2 g/day Nigella sativa (NS-2)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Placebo (Control)
Number of subjects: 74
Study: 25734911

Group type: EXPERIMENTAL
Intervention: Continuous Resistance Training (CRT)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Periodic Resistance Training (PRT)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Both groups (CRT and PRT)
Number of subjects: 18
Study: 22897742

Group type: EXPERIMENTAL
Intervention: Magnetic mallet group (MMG)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Hand mallet group (HMG)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 50
Study: 21851195

Group type: EXPERIMENTAL
Intervention: D-cycloserine (50 mg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 19631846

Group type: EXPERIMENTAL
Intervention: Pulpectomy procedures
Number of subjects: 0
Study: 17244178

Group type: EXPERIMENTAL
Intervention: Intensive group cognitive treatment (IGCT)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Individual cognitive therapy (ICT)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 100
Study: 15908654

Group type: EXPERIMENTAL
Intervention: Group education and counseling
Number of subjects: 142

Group type: COMPARATOR
Intervention: Individual education and counseling
Number of subjects: 142
Study: 12518490

Group type: EXPERIMENTAL
Intervention: Crest SpinBrush Pro (experimental powered toothbrush)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Oral-B CrossAction (advanced-design manual toothbrush)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Oral-B 40 Indicator (flat-trimmed toothbrush)
Number of subjects: 140
Study: 9807345

Group type: EXPERIMENTAL
Intervention: Peplau's process of practice-based theory development
Number of subjects: 0
Study: 8604868

Group type: EXPERIMENTAL
Intervention: 1% lidocaine/.25% bupivacaine
Number of subjects: 19

Group type: COMPARATOR
Intervention: .25% bupivacaine alone
Number of subjects: 19
Study: 1958449

Group type: EXPERIMENTAL
Intervention: RG 12525 800 mg
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 7217707

Group type: EXPERIMENTAL
Intervention: Coagulation studies
Number of subjects: 32
Study: 31478963

Group type: EXPERIMENTAL
Intervention: Fast Alcohol Screening Test
Number of subjects: 764

Group type: EXPERIMENTAL
Intervention: Glasgow Modified Alcohol Withdrawal Scale score
Number of subjects: 764

Group type: EXPERIMENTAL
Intervention: AWS admission
Number of subjects: 764

Group type: EXPERIMENTAL
Intervention: Hours since the last drink
Number of subjects: 764

Group type: EXPERIMENTAL
Intervention: Systolic blood pressure
Number of subjects: 764

Group type: COMPARATOR
Intervention: Comorbidity
Number of subjects: 764
Study: 28464041

Group type: EXPERIMENTAL
Intervention: PopART intervention (universal testing and treatment)
Number of subjects: 121130
Study: 24639003

Group type: EXPERIMENTAL
Intervention: Spiral EPI navigator
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Cartesian EPI navigator
Number of subjects: 8

Group type: COMPARATOR
Intervention: Radial navigator
Number of subjects: 8
Study: 23195630

Group type: EXPERIMENTAL
Intervention: Overload group (OR) during 3 weeks of training
Number of subjects: 24

Group type: COMPARATOR
Intervention: Normo-trained group (NT) during 3 weeks of training
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Maximal incremental test parameters
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Heart rate and blood lactate concentration changes
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Cognitive performance
Number of subjects: 24
Study: 20924024

Group type: EXPERIMENTAL
Intervention: Intervention group (n = 69)
Number of subjects: 139

Group type: COMPARATOR
Intervention: Control group (n = 70)
Number of subjects: 139
Study: 19468036

Group type: EXPERIMENTAL
Intervention: Bupivacaine
Number of subjects: 40

Group type: COMPARATOR
Intervention: Normal Saline
Number of subjects: 40
Study: 17361851

Group type: EXPERIMENTAL
Intervention: Multifaceted intervention including deltamethrin-impregnated bednets, repellent (20% diethyltoluamide and 0.5% permethrin), modification of sand fly resting sites, and health education.
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (no intervention).
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Multifaceted intervention.
Number of subjects: 20
Study: 15332389

Group type: EXPERIMENTAL
Intervention: Montelukast 10 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Montelukast 40 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 10943876

Group type: EXPERIMENTAL
Intervention: Low-dose oral methotrexate (MTX) 15 mg/m2 (increased to 20 mg/m2 after 2 months)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Low-dose oral methotrexate (MTX)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 88
Study: 1736617

Group type: EXPERIMENTAL
Intervention: Dofetilide (1 of 2 dose levels)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Dofetilide (high-dose level)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 6500758

Group type: EXPERIMENTAL
Intervention: Brand A of furosemide
Number of subjects: 16

Group type: COMPARATOR
Intervention: Brand B of furosemide
Number of subjects: 16
Study: 31564933

Group type: EXPERIMENTAL
Intervention: PEDYPHAR ointment
Number of subjects: 119

Group type: COMPARATOR
Intervention: Panthenol ointment (control)
Number of subjects: 119
Study: 30594223

Group type: EXPERIMENTAL
Intervention: Incentive Scheme with motivational interviewing; gift vouchers of US$5.6 for VL < 20 copies/mL at 12 weeks, US$2.8 for VL suppression for the next 3 months, US$5.6 for VL < 20 copies/mL at 1 year.
Number of subjects: 12

Group type: COMPARATOR
Intervention: Routine HIV care (usual care)
Number of subjects: 12
Study: 27623720

Group type: EXPERIMENTAL
Intervention: 5% phenol in almond oil
Number of subjects: 80

Group type: COMPARATOR
Intervention: 50% dextrose water
Number of subjects: 80
Study: 25027180

Group type: EXPERIMENTAL
Intervention: r‐ADP‐agg ≥ 50%
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: ACS-setting
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: Severely reduced LV function
Number of subjects: 184
Study: 22122605

Group type: EXPERIMENTAL
Intervention: Exergame training (24 sessions of 1 hour each)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group without treatment
Number of subjects: 0
Study: 19917571

Group type: EXPERIMENTAL
Intervention: PI-88 in combination with docetaxel (75 mg/m2 every three weeks)
Number of subjects: 56
Study: 18381807

Group type: EXPERIMENTAL
Intervention: Non-drained group
Number of subjects: 116

Group type: COMPARATOR
Intervention: Drained group
Number of subjects: 116
Study: 16231269

Group type: EXPERIMENTAL
Intervention: Bacterial interference with Escherichia coli 83972
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study: 12646667

Group type: EXPERIMENTAL
Intervention: Abciximab
Number of subjects: 1088

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1088
Study: 10229064

Group type: EXPERIMENTAL
Intervention: Lorazepam (6 mg/day)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 8912562

Group type: EXPERIMENTAL
Intervention: Oral calcitriol (0.5 to 2 micrograms daily)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: UVB phototherapy
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 1819620

Group type: EXPERIMENTAL
Intervention: 1 g i.v. of imipenem‐cilastatin at induction of anesthesia
Number of subjects: 61

Group type: COMPARATOR
Intervention: Cefuroxime (1.5 g i.v.) plus metronidazole (0.5 g i.v.) at the time of anesthesia and two other administrations of the combined antibiotics (cefuroxime 0.75 g plus metronidazole 0.5 g i.v.) every 8 hours
Number of subjects: 61
Study: 6698566

Group type: EXPERIMENTAL
Intervention: Ethanol (0.8 g/kg)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Meptazinol (200 mg 3 hourly for 4 doses)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Meptazinol (200 mg 3 hourly for 4 doses) + Ethanol (0.8 g/kg)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 30961456

Group type: EXPERIMENTAL
Intervention: Stanford orientation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control orientation
Number of subjects: 0
Study: 29526852

Group type: EXPERIMENTAL
Intervention: Automated Mechanical Peripheral Stimulation (AMPS), n = 16
Number of subjects: 33

Group type: COMPARATOR
Intervention: AMPS SHAM, n = 17
Number of subjects: 33
Study: 26597401

Group type: EXPERIMENTAL
Intervention: SPRM/CDSS intervention
Number of subjects: 361

Group type: COMPARATOR
Intervention: Standard pharmaceutical care (control)
Number of subjects: 361
Study: 24428351

Group type: EXPERIMENTAL
Intervention: HeRO Graft
Number of subjects: 143

Group type: COMPARATOR
Intervention: Conventional AV graft
Number of subjects: 143
Study: 23672904

Group type: EXPERIMENTAL
Intervention: Semi-extended, extra-articular, parapatellar approach intramedullary nail
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control group (uninjured patients)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Fracture group
Number of subjects: 18
Study: 21045674

Group type: EXPERIMENTAL
Intervention: Sodium hyaluronate (0.1%)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Carboxymethylcellulose (0.5%)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Both SH and CMC
Number of subjects: 67
Study: 18787526

Group type: EXPERIMENTAL
Intervention: Tailored weight loss intervention
Number of subjects: 144

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 144
Study: 16525856

Group type: EXPERIMENTAL
Intervention: SSRI treatment
Number of subjects: 32
Study: 14602694

Group type: EXPERIMENTAL
Intervention: Indomethacin 0.2 mg/kg
Number of subjects: 111

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Indomethacin (after 2 hours)
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Failed ductal constriction
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Initial SVC flow
Number of subjects: 111
Study: 11024412

Group type: EXPERIMENTAL
Intervention: Laser photocoagulation
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Submacular surgery
Number of subjects: 70
Study: 8758193

Group type: EXPERIMENTAL
Intervention: High dose chemotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Best conventional therapy
Number of subjects: 0
Study: 1514713

Group type: EXPERIMENTAL
Intervention: Sodium meglumine ioxaglate
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Iohexol
Number of subjects: 80
Study: 6581492

Group type: EXPERIMENTAL
Intervention: Lithium plus acute haloperidol
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Lithium plus chronic haloperidol
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Lithium
Number of subjects: 9
Study: 31442202

Group type: EXPERIMENTAL
Intervention: Attended stimuli
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 30092411

Group type: EXPERIMENTAL
Intervention: Monotherapy (amlodipine 10 mg od; lisinopril 20 mg od; chlorthalidone 25 mg od)
Number of subjects: 1320

Group type: EXPERIMENTAL
Intervention: Dual therapy (amlodipine 5 mg od and lisinopril 20 mg od; amlodipine 5 mg od and chlorthalidone 25 mg od; lisinopril 20 mg od and chlorthalidone 25 mg od; amiloride 10 mg od and chlorthalidone 25 mg od)
Number of subjects: 1320
Study: 27329829

Group type: EXPERIMENTAL
Intervention: Coronally advanced flap with connective tissue graft (CAF + CTG)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Coronally advanced flap alone (CAF)
Number of subjects: 32
Study: 24605986

Group type: EXPERIMENTAL
Intervention: Holiday food cues (Study 1)
Number of subjects: 262

Group type: EXPERIMENTAL
Intervention: Holiday food cues (Study 2)
Number of subjects: 262

Group type: COMPARATOR
Intervention: Neutral topic (Study 2)
Number of subjects: 262
Study: 22907609

Group type: EXPERIMENTAL
Intervention: Lidocaine (1.5 mg kg(‐1) bolus during induction, followed by 2 mg kg(‐1) h(‐1) intraoperative infusion and 1.3 mg kg(‐1) h(‐1) for 24 h postoperatively)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Lidocaine
Number of subjects: 64
Study: 20807345

Group type: EXPERIMENTAL
Intervention: Fentanyl buccal tablet (FBT)
Number of subjects: 148

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 148
Study: 16935035

Group type: EXPERIMENTAL
Intervention: Inhaled furosemide (40 mg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 16388684

Group type: EXPERIMENTAL
Intervention: Center of pressure (COP) measures during reaching and leaning tasks
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Center of pressure (COP) measures during reaching expressed as a percentage of maximum COP displacement during leaning
Number of subjects: 21

Group type: COMPARATOR
Intervention: Berg Balance Scale (BBS), Mini‐mental State Exam, Expanded Disability Status Scale (EDSS), Multiple Sclerosis Functional Composite (MSFC)
Number of subjects: 21
Study: 12572373

Group type: EXPERIMENTAL
Intervention: Combined therapy of methotrexate (MTX), sulfasalazine (SSZ) and Fengshi No. 1 (FS1)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Methotrexate (MTX) and sulfasalazine (SSZ) alone
Number of subjects: 60
Study: 9440376

Group type: EXPERIMENTAL
Intervention: Lysine intake of 12 mg.kg‐1.d‐1
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Lysine intake of 28 mg.kg‐1.d‐1
Number of subjects: 7
Study: 8595517

Group type: EXPERIMENTAL
Intervention: IL-1ra (100 mg bolus followed by 2.0 mg/kg/h i.v. for 72 h)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 2235951

Group type: EXPERIMENTAL
Intervention: Tisamid plus isoniazid, rifampicin, and streptomycin (or ethambutol)
Number of subjects: 145

Group type: COMPARATOR
Intervention: Isoniazid, rifampicin, and streptomycin (or ethambutol)
Number of subjects: 145
Study: 227571

Group type: EXPERIMENTAL
Intervention: Combination of CCNA, methotrexate, and adriamycin in epidermoid carcinoma
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: Combination of CCNU, cyclophosphamide, and methotrexate in adenocarcinoma
Number of subjects: 147

Group type: COMPARATOR
Intervention: Combination of cyclophosphamide and adriamycin
Number of subjects: 147

Group type: COMPARATOR
Intervention: Combination of CCNU, procarbazine, and 5-fluorouracil
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: Objective responders and stable responders
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: Complete remission in epidermoid carcinoma
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: Patients ≥50% bedridden
Number of subjects: 147
Study: 30465868

Group type: EXPERIMENTAL
Intervention: Texture analysis on T2w FLAIR MRI
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Texture analysis on ADC MRI
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Texture analysis on T1w MRI
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Texture analysis on T1w + Gd MRI
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: MDF values for discrimination
Number of subjects: 41

Group type: COMPARATOR
Intervention: Histogram parameters
Number of subjects: 41
Study: 27461168

Group type: EXPERIMENTAL
Intervention: Sorghum bicolor extract (500 mg/d) + folic acid (5 mg/d) + iron (200 mg three times daily)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Routine hematinics (folic acid 5 mg/d and iron 200 mg three times daily)
Number of subjects: 66
Study: 25068560

Group type: EXPERIMENTAL
Intervention: Usual care plus OMT (OMT)
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Usual care plus placebo ultrasound treatment (PUT)
Number of subjects: 400

Group type: COMPARATOR
Intervention: Usual care only (UCO)
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Secondary outcome of meconium-stained amniotic fluid
Number of subjects: 400